AtriCure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AtriCure, Inc. on January 12, 2026, covering events occurring on January 9, 2026. The filing primarily addresses a material amendment to the company's credit facility and references preliminary financial results for the fourth quarter and full year ended December 31, 2025.
Key Financial Metrics and Debt Structure
The filing details the terms of an amended Asset-Based Lending (ABL) Facility rather than providing specific revenue or profit figures for the period.
- Credit Facility: An asset-based revolving credit facility with a maximum commitment of $125 million.
- Expansion Option: Borrowers may request an increase of up to $40 million, bringing the total potential commitment to $165 million.
- Letters of Credit: Up to $5 million of the facility is available for letters of credit.
- Interest Rate: The amendment provides for a reduction in the overall interest rate on loans under the ABL Facility.
- Covenants: The minimum utilization financial covenant has been removed.
- Collateral: The facility is secured by a first priority perfected security interest in all assets of the Borrowers, including equity interests of direct subsidiaries (limited to less than 65% for foreign subsidiaries to avoid adverse tax consequences).
Note: Specific revenue, profit, cash flow, and margin figures for the fourth quarter and full year 2025 are not contained within the text of this filing; they are referenced in a press release (Exhibit 99.1) which is not included in the provided source text.
Material Changes
On January 9, 2026, the Company entered into a First Amendment to its Credit Agreement with JPMorgan Chase Bank, N.A. Key changes include:
- Term Extension: The term of the Credit Agreement has been extended by three years.
- Cost Reduction: Implementation of a lower overall interest rate.
- Covenant Relief: Removal of the minimum utilization financial covenant.
Outlook, Risks, and Management Commentary
The ABL Facility is designated to finance working capital needs and general corporate purposes. The filing notes that the information regarding preliminary financial results (Item 2.02) is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference in future filings unless expressly stated.
Investor Verification Checklist
- Review the full text of the First Amendment to the Credit Agreement (Exhibit 10.1) for specific interest rate calculations and fee structures.
- Obtain the press release dated January 12, 2026 (Exhibit 99.1) to verify actual revenue, net income, and cash flow figures for Q4 and FY 2025.
- Confirm the current utilization rate of the $125 million ABL Facility to assess immediate liquidity headroom.
- Verify the status of the $40 million accordion expansion option and any conditions precedent required to exercise it.